Zacks Research Forecasts Weaker Earnings for SeaStar Medical

SeaStar Medical Holding Corporation (NASDAQ:ICU) – Zacks Research cut their Q3 2026 EPS estimates for shares of SeaStar Medical in a research report issued on Monday, August 17th. Zacks Research analyst D. Bautz now forecasts that the company will post earnings per share of ($0.95) for the quarter, down from their previous estimate of ($0.89). The consensus estimate for SeaStar Medical’s current full-year earnings is ($3.58) per share. Zacks Research also issued estimates for SeaStar Medical’s FY2026 earnings at ($3.66) EPS.

Several other research firms also recently weighed in on ICU. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of SeaStar Medical in a research note on Friday, July 17th. Wall Street Zen raised SeaStar Medical from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Finally, Maxim Group set a $8.00 price target on shares of SeaStar Medical and gave the stock a “buy” rating in a report on Thursday, May 14th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $8.00.

SeaStar Medical Stock Down 2.1%

ICU stock opened at $3.27 on Thursday. The firm has a market cap of $14.42 million, a price-to-earnings ratio of -0.84 and a beta of -1.05. SeaStar Medical has a twelve month low of $2.07 and a twelve month high of $12.50. The business’s fifty day simple moving average is $3.69 and its two-hundred day simple moving average is $3.43.

SeaStar Medical (NASDAQ:ICU) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.91) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.06. SeaStar Medical had a negative net margin of 795.51% and a negative return on equity of 162.75%. The company had revenue of $0.61 million for the quarter, compared to analyst estimates of $0.49 million.

Hedge Funds Weigh In On SeaStar Medical

Large investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd raised its position in shares of SeaStar Medical by 395.4% during the 2nd quarter. XTX Topco Ltd now owns 60,983 shares of the company’s stock worth $26,000 after purchasing an additional 48,674 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of SeaStar Medical in the 4th quarter worth $30,000. Finally, Millennium Management LLC purchased a new position in SeaStar Medical during the third quarter worth about $102,000. 1.69% of the stock is currently owned by institutional investors and hedge funds.

About SeaStar Medical

SeaStar Medical, Inc (NASDAQ: ICU) is a medical device company focused on the development and commercialization of cerebral embolic protection systems for patients undergoing transcatheter aortic valve replacement (TAVR) procedures. The company’s mission is to reduce the risk of stroke and other neurologic events associated with structural heart interventions by capturing or deflecting embolic debris that can travel to the brain during catheter-based therapies.

The company’s flagship product, TriGUARD® 3, is a next-generation embolic deflection device designed to provide coverage of all three cerebral vessels during TAVR.